Trials / Completed
CompletedNCT02654470
Watchman FLX Left Atrial Appendage Closure Device Post Approval Study ( Europe Only)
Watchman FLX Left Atrial Appendage Closure Device Post Approval Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (actual)
- Sponsor
- Boston Scientific Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Watchman FLX Left Atrial Appendage Closure Device Post Approval Study
Detailed description
WATCHMAN FLX is intended to prevent thrombus embolization from the left atrial appendage and reduce the risk of life-threatening bleeding events in patients with non-valvular atrial fibrillation who are eligible for anticoagulation therapy or who have a contraindication to anticoagulation therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Watchman FLX | Patients who are receiving the Watchman FLX device |
Timeline
- Start date
- 2019-07-16
- Primary completion
- 2021-09-28
- Completion
- 2021-09-28
- First posted
- 2016-01-13
- Last updated
- 2021-11-19
Locations
17 sites across 9 countries: Denmark, France, Germany, Ireland, Italy, Netherlands, Poland, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02654470. Inclusion in this directory is not an endorsement.